| IVZ |
Report |
Adjusted EPS |
BEAT |
pred ~$0.69 vs. cons $0.67 |
MEDIUM |
| IVZ |
Report |
Adjusted net revenue |
BEAT |
pred ~$1.34B vs. cons $1.314B |
MEDIUM |
| IVZ |
Report |
Adjusted operating margin |
BEAT |
pred ~38.7% vs. cons 38.0% |
MEDIUM |
| IVZ |
Guide |
Adjusted operating expenses |
LOWER |
guide ~$3.30B vs. cons $3.32B (FY2026) |
MEDIUM |
| IVZ |
Guide |
Adjusted operating margin commentary |
BETTER |
guide ~39.0% vs. cons 38.5% (Q3 2026) |
LOW |
| IVZ |
Guide |
Hybrid-platform cost savings |
UNCHANGED |
guide ~$60M vs. cons $60M (FY2027) |
HIGH |
| IVZ |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.8% |
— |
MEDIUM |
| IVZ |
Return |
5-day cumulative residual |
+3.8% (FOLLOW-THROUGH) |
FY2026 expense guidance of ~$3.30B vs. consensus $3.32B and Q3 margin commentary of ~39.0% vs. consensus 38.5% should lift out-period EPS estimates, allowing the day-1 residual of ~2.8% to extend to ~3.8% cumulatively by day 5. |
MEDIUM |